Altered GABA Signaling in Early Life Epilepsies

• Published in: Journal of neural transplantation & plasticity Vol. 2011; no. 2011; pp. 161 - 176
• Main Authors: Briggs, Stephen W., Galanopoulou, Aristea S.
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Limiteds 01.01.2011; Hindawi Puplishing Corporation; Hindawi Publishing Corporation; John Wiley & Sons, Inc; Wiley
• Subjects: Aging - metabolism; Child, Preschool; Drug therapy; Epilepsy; Epilepsy - complications; Epilepsy - metabolism; Epilepsy - physiopathology; Female; GABA; gamma-Aminobutyric Acid - metabolism; Humans; Infant; Infant, Newborn; Male; Physiological aspects; Potassium Channels - metabolism; Receptors, GABA-A - metabolism; Review; Risk Factors; Seizures (Medicine); Seizures - etiology; Seizures - metabolism; Sex Factors; Signal Transduction; United States
• ISSN: 0792-8483; 2090-5904; 1687-5443
• DOI: 10.1155/2011/527605

The incidence of seizures is particularly high in the early ages of life. The immaturity of inhibitory systems, such as GABA, during normal brain development and its further dysregulation under pathological conditions that predispose to seizures have been speculated to play a major role in facilitating seizures. Seizures can further impair or disrupt GABAA signaling by reshuffling the subunit composition of its receptors or causing aberrant reappearance of depolarizing or hyperpolarizing GABAA receptor currents. Such effects may not result in epileptogenesis as frequently as they do in adults. Given the central role of GABAA signaling in brain function and development, perturbation of its physiological role may interfere with neuronal morphology, differentiation, and connectivity, manifesting as cognitive or neurodevelopmental deficits. The current GABAergic antiepileptic drugs, while often effective for adults, are not always capable of stopping seizures and preventing their sequelae in neonates. Recent studies have explored the therapeutic potential of chloride cotransporter inhibitors, such as bumetanide, as adjunctive therapies of neonatal seizures. However, more needs to be known so as to develop therapies capable of stopping seizures while preserving the age- and sex-appropriate development of the brain.